X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (416) 416
Publication (70) 70
Book Chapter (4) 4
Newspaper Article (3) 3
Book Review (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (222) 222
index medicus (166) 166
infectious diseases (164) 164
pharmacology & pharmacy (128) 128
female (118) 118
hiv infections - drug therapy (118) 118
adult (115) 115
male (111) 111
microbiology (100) 100
hiv (84) 84
immunology (82) 82
middle aged (82) 82
pharmacokinetics (75) 75
anti-hiv agents - pharmacokinetics (59) 59
human immunodeficiency virus--hiv (56) 56
protease inhibitors (56) 56
antiretroviral drugs (55) 55
antiretroviral therapy (55) 55
virology (54) 54
drug interactions (53) 53
pharmacology (51) 51
anti-hiv agents - therapeutic use (49) 49
efavirenz (43) 43
young adult (37) 37
drug therapy (36) 36
anti-hiv agents - administration & dosage (35) 35
antiviral agents (35) 35
plasma (33) 33
ritonavir (30) 30
hiv infections - virology (27) 27
therapy (27) 27
article (26) 26
aids/hiv (25) 25
anti-hiv agents - blood (25) 25
hiv infections - blood (25) 25
hiv protease inhibitors - pharmacokinetics (25) 25
human-immunodeficiency-virus (25) 25
adolescent (24) 24
aged (24) 24
area under curve (24) 24
drug therapy, combination (24) 24
nevirapine (24) 24
drug dosages (23) 23
viral load (23) 23
hiv-1 - drug effects (22) 22
p-glycoprotein (22) 22
plasma-concentrations (22) 22
tuberculosis (22) 22
hiv infection (21) 21
in-vitro (21) 21
nevirapine - pharmacokinetics (21) 21
pharmacogenetics (21) 21
reverse transcriptase inhibitors - pharmacokinetics (21) 21
ritonavir - pharmacokinetics (21) 21
saquinavir (21) 21
lopinavir (20) 20
ritonavir - administration & dosage (20) 20
drugs (19) 19
hiv infections - complications (19) 19
hiv infections - metabolism (19) 19
analysis (18) 18
anti-hiv agents - adverse effects (18) 18
hiv-infected patients (18) 18
infection (18) 18
plasma - chemistry (18) 18
tenofovir (18) 18
healthy-volunteers (17) 17
hiv protease inhibitors - therapeutic use (17) 17
human immunodeficiency virus (17) 17
research (17) 17
aids (16) 16
antiretroviral therapy, highly active (16) 16
clinical trials (16) 16
nevirapine - therapeutic use (16) 16
reverse transcriptase inhibitors - therapeutic use (16) 16
hiv-1 (15) 15
lamivudine (15) 15
cd4 lymphocyte count (14) 14
cohort studies (14) 14
genotype (14) 14
highly active antiretroviral therapy (14) 14
malawi (14) 14
pregnancy (14) 14
resistance (14) 14
safety (14) 14
united kingdom (14) 14
virus diseases (14) 14
animals (13) 13
antiretroviral agents (13) 13
benzoxazines - pharmacokinetics (13) 13
blood mononuclear-cells (13) 13
dosage and administration (13) 13
dose-response relationship, drug (13) 13
drug administration schedule (13) 13
efficacy (13) 13
original research (13) 13
prospective studies (13) 13
reverse-transcriptase inhibitors (13) 13
uganda (13) 13
adults (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 53 - 60
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 4/2008, Volume 61, Issue 4, pp. 914 - 918
Journal Article
PLoS One, ISSN 1932-6203, 2017, Volume 12, Issue 3, p. e0173509
Journal Article
Drugs, ISSN 0012-6667, 2010, Volume 70, Issue 18, pp. 2373 - 2407
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2014, Volume 58, Issue 7, pp. 928 - 936
Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs... 
sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | POTENT | BI 201335 | HIV | INHIBITOR | ANTIRETROVIRAL TREATMENT | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Hepacivirus | Sofosbuvir | Economic aspects | Antiviral agents | Production management | Care and treatment | Hepatitis C | and Commentaries
Journal Article
Clinical pharmacokinetics, 08/2019, Volume 58, Issue 12, pp. 1553 - 1565
Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that has demonstrated good efficacy, tolerability, and safety for the treatment of... 
Index Medicus
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2019, Volume 63, Issue 6
Journal Article
Journal Article